Citing enrollment challenges, Bristol Myers and 2seventy scrap Abecma trial in first-line myeloma
Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma has hit a major setback. Bristol and its partner 2seventy bio have decided to pull the plug on the phase 3 KarMMa-9 trial in first-line myeloma after struggling to enroll patients.
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval in April.
BMS and 2seventy bio to discontinue enrolment in multiple myeloma trial
Despite being open for over a year across 18 countries, the trial managed to recruit only 10% of its target population.
2seventy, Bristol Myers Discontinue Enrollment In Phase 3 KarMMa-9 Study - Quick Facts
(RTTNews) - 2seventy bio (TSVT) announced that the company, in partnership with study sponsor Bristol Myers Squibb, will discontinue enrollment
BMS, 2seventy End Phase III Trial of Maintenance Abecma in Multiple Myeloma Due to Low Enrollment
NEW YORK – Bristol Myers Squibb and 2seventy bio said on Wednesday they are discontinuing enrollment in the Phase III KarMMa-9 study evaluating maintenance treatment with CAR T-cel therapy Abecma (idecabtagene vicleucel) with immunomodulator Revlimid (lenalidomide) in patients with newly diagnosed multiple myeloma.
Bristol Myers, 2seventy bio halt enrollment in Abecma late-stage trial
(TSVT) stock lost as company with Bristol Myers Squibb (BMY) plan to discontinue enrollments in a Phase 3 trial for cancer drug Abecma. Read more here.
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with ...
Zacks.com on MSN1d
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
TSVT announced that it will discontinue enrollment in its ongoing phase III KarMMa-9 study.The study is evaluating Abecma ...
MedPage Today1d
Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement
(Endpoints News) Bristol Myers Squibb and 2seventy bio announced discontinuation of enrollment in the phase III KarMMa-9 ...
The Pharma Letter2d
2seventy bio and BMS to drop KarMMa-9 study
US biotech 2seventy bio and partner Bristol Myers Squibb today revealed that they will discontinue enrollment in its ongoing ...
BioPharma Dive2d
Struggling 2Seventy scraps a key cancer study
The biotech expects that stopping enrollment for KarMMa-9, a trial evaluating early use of the multiple myeloma cell therapy Abecma, should save it $80 million in the near term.
Business Insider15h
Bristol-Myers Squibb: Sell Rating Justified by Market Challenges and Drug Uptake Concerns
Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target remains the same with $37.00. Terence Flynn has ...